CEO Ole Thastrup comments:
"I would like to start by thanking all who showed interest to subscribe for shares in 2cureX. It is gratifying that the interest for our company is so big and that we can welcome many new owners. With the proceeds, we will be able to finance all the preparatory activities before the market launch of IndiTreat™, for example, CE marking and ISO certification, building the sales organization and establishment of additional test-sites. "
Subscription and allocation
The new issue was subscribed to approx. 65.2 MSEK, equivalent to 2 350 000 shares. 2cureX is supplied with approx. 18.3 MSEK before transaction costs, which are expected to amount to around 1.7 MSEK. In view of the widespread interest in the rights issue, it has not been possible to assign a minimum subscription of 700 shares to all subscribers in the rights issue. The assignment has been made in accordance with the principles set out in the company's memorandum.
Listing on Nasdaq OMX First North
2cureX will apply to list its shares on Nasdaq OMX Stockholm First North. The first day of trading is scheduled to be on November 24th, 2017.
Number of shares and share capital
When 2cureX's rights issue has been registered at the Swedish Companies Registration Office (Bolagsverket), the total number of shares will amount to 10 350 000 shares and the share capital will amount to SEK 1 035 000.
Financial advisor and Certified Adviser
Sedermera fondkommission is financial advisor to 2cureX in connection with the rights issue and the planned listing on the Nasdaq OMX Stockholm First North. Sedermera fondkommission is also designated as a Certified Adviser for the company.
For more information on the rights issue and of the planned listing, please contact:
Telefon: +46 40 615 14 10
For more information on 2cureX, please contact:
Ole Thastrup, CEO
Phone: +45 22 11 53 99
2cureX is a Danish company that has developed the IndiTreat™ method. IndiTreat™ matches the individual patient with the most effective treatment. The first IndiTreat™ product is directed towards colorectal cancer. IndiTreat™ has the potential to be used in other cancer indications.